CD274 and neoplasm: In recent years, immunotherapy has emerged as a transformative clinical strategy for cancer treatment.[48] Tumor cells often upregulate PD‐L1 expression, exploiting the PD‐L1/PD‐1 signaling axis to evade T cell‐mediated immune responses.[49, 50] Blockade of the PD‐L1/PD‐1 pathway has been shown to elicit robust anti‐tumor effects in patients with advanced cancers,[51, 52, 53] establishing this approach as a cornerstone for developing immune checkpoint blockade (ICB) therapies and combination regimens.